Published in J Infect Dis on July 31, 2013
A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS (2014) 0.89
Identifying the appropriate comparison group for HIV-infected individuals. Curr Opin HIV AIDS (2014) 0.81
Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. AIDS Res Treat (2015) 0.80
Factors associated with iohexol-based glomerular filtration rate slope over 36 months in HIV-negative and HIV-positive individuals. AIDS (2016) 0.78
Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis. J Viral Hepat (2015) 0.77
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients. AIDS (2016) 0.76
Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014. AIDS (2016) 0.76
Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine. Int J Mol Sci (2015) 0.75
Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis (2016) 0.75
Proteinuria is common among HIV patients: what are we missing? Clinics (Sao Paulo) (2015) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int (2010) 9.25
Epidemiology of viral hepatitis and HIV co-infection. J Hepatol (2005) 6.41
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA (1997) 5.09
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis (2008) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA (1997) 2.06
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol (2007) 1.57
Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis (2011) 1.48
Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med (2007) 1.45
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
The association of poverty with the prevalence of albuminuria: data from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis (2006) 1.36
The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS (2008) 1.30
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS (2012) 1.16
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One (2012) 1.16
Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol (2006) 1.15
Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis (2008) 1.12
Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: reversal by coincubation with sigma-receptor antagonists. Circulation (1998) 1.12
HCV infection and the incidence of CKD. Am J Kidney Dis (2010) 1.11
Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol (2007) 1.03
Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol (1999) 0.98
Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis (1997) 0.95
Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis (2009) 0.95
The impact of hepatitis C coinfection on kidney disease related to human immunodeficiency virus (HIV): a biopsy study. Medicine (Baltimore) (2011) 0.93
Cocaine-induced renal disease. Expert Opin Drug Saf (2004) 0.85
Kidney vascular damage and cocaine. Clin Nephrol (1997) 0.84
Nutrition issues in the HIV-infected injection drug user: findings from the nutrition for healthy living cohort. J Am Coll Nutr (2010) 0.81
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med (2010) 11.99
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Tuberculosis. Lancet (2003) 6.39
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Veterans Aging Cohort Study (VACS): Overview and description. Med Care (2006) 4.34
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
De facto long-term opioid therapy for noncancer pain. Clin J Pain (2008) 3.85
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Targeting of GFP to newborn rods by Nrl promoter and temporal expression profiling of flow-sorted photoreceptors. Proc Natl Acad Sci U S A (2006) 3.27
Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med (2006) 3.25
Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf (2009) 3.25
Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care (2005) 3.19
Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis (2008) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med (2010) 3.00
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Increased COPD among HIV-positive compared to HIV-negative veterans. Chest (2006) 2.93
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis (2005) 2.92
Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs (2006) 2.89
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (2006) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med (2005) 2.58
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS (2003) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol (2006) 2.46
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis (2004) 2.44
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int (2002) 2.31
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24
Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults. Clin Infect Dis (2012) 2.24
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (2009) 2.22
Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr (2012) 2.19